



Authorised Use

The Ministry of Health and Prevention in United Arab Emirates (MOHAP) has approved the use of the PAXLOVID™ that is used in adults 18 years of age and older with mild to moderate COVID 19. It is only used in patients who are at high risk for progression to severe COVID 19, including hospitalisation or death.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

The patient information leaflet linked to the QR Code on the product pack has the latest updated product information approved in your country, which may be more up to date than the paper leaflet.

[Read the PAXLOVID™ Package Leaflet: Information for the Patient](#)



[نشرة العبوة: معلومات للمريض](#)

